Understand the source comparison
AICAR versus metformin
Metformin, the most widely prescribed type-2-diabetes drug, activates AMPK indirectly by mildly inhibiting mitochondrial complex I, which raises the cellular AMP/ATP ratio. Unlike AICAR, metformin has an enormous human safety and efficacy record — but for a li
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Metformin, the most widely prescribed type-2-diabetes drug, activates AMPK indirectly by mildly inhibiting mitochondrial complex I, which raises the cellular AMP/ATP ratio. Unlike AICAR, metformin has an enormous human safety and efficacy record — but for a licensed indication (glycemic control), not for endurance or longevity, where it is still under active investigation. The contrast is instructive: metformin shows that AMPK activation can be clinically useful and safe when the molecule has good pharmacokinetics and a defined indication, while also showing that decades of human data are what separate a medicine from a mechanism. It is also a caution against the intuitive leap that “AICAR and metformin both activate AMPK, therefore AICAR should share metformin’s benefits.” The two engage the pathway by entirely different routes — metformin indirectly, by raising the AMP/ATP ratio through complex-I inhibition; AICAR directly, through an AMP-mimetic metabolite — and they differ enormous